VistaGen Therapeutics, Inc. (VSTA) Starts Presentation at WALL ST. Conference

VistaGen Therapeutics is developing innovative medicine for depression and diseases and conditions involving the central nervous system (CNS). The company’s AV-101 is a new generation orally available anti-depressant candidate entering phase 2 clinical development. Based on preclinical studies, AV-101 may also have potential as a treatment for other CNS-related conditions and neurodegenerative diseases. VistaGen is also leveraging its proprietary pluripotent stem cell technology and clinically predictive bioassay systems, CardioSafe 3D™ and LiverSafe 3D™, for drug rescue applications.  For more information visit the company’s website at: www.vistagen.com